Clinical trial • Phase IV • Infectious Disease
ERYTHROMYCIN for Surgical site infection
Phase IV trial of ERYTHROMYCIN for Surgical site infection. Randomised. 322 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Surgical site infection
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 28-01-2025
- First CTIS Authorization Date
- 30-01-2025
Trial design
Randomised Phase IV trial across 1 site in Ireland.
- Randomised
- Yes
- Target Sample Size
- 322
Eligibility
Recruits 322 Vulnerable population not selected; trial enrols adults (≥ 18 years). Inability to provide informed consent is listed as an exclusion criterion..
- Pregnancy Exclusion
- (9) Patients who have a positive pregnancy test.
- Vulnerable Population
- Vulnerable population not selected; trial enrols adults (≥ 18 years). Inability to provide informed consent is listed as an exclusion criterion.
Inclusion criteria
- {"criterion_text":"- Adult patients (aged ≥ 18 years) scheduled for elective laparoscopic, open and/or robotic assisted colon or rectal surgery for benign or malignant disease"}
Exclusion criteria
- {"criterion_text":"- 1) inability to provide informed consent"}
- {"criterion_text":"- (2) acute surgery for bleeding, perforation or obstruction"}
- {"criterion_text":"- (3) uncontrolled diabetes mellitus"}
- {"criterion_text":"- (4) preoperative steroid use"}
- {"criterion_text":"- (5) antibiotic use within 2 weeks of proposed elective surgery date"}
- {"criterion_text":"- and (6) previous allergic reaction to the antibiotics utilised in this study."}
- {"criterion_text":"- (7) Patients with contraindications to neomycin and erythromycin."}
- {"criterion_text":"- (8) Patients with renal and hepatic impairment."}
- {"criterion_text":"- (9) Patients who have a positive pregnancy test."}
- {"criterion_text":"- (10) Patients requiring more extensive antibiotic prophylaxis."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Incidence of surgical site infection","definition_or_measurement_approach":""}
Secondary endpoints
- {"endpoint_text":"- Infectious complications other than surgical site infections","definition_or_measurement_approach":""}
- {"endpoint_text":"- length of hospital stay","definition_or_measurement_approach":""}
- {"endpoint_text":"- postoperative complications as per Clavien Dindo Classification","definition_or_measurement_approach":""}
- {"endpoint_text":"- anastomotic leakage","definition_or_measurement_approach":""}
- {"endpoint_text":"- mortality","definition_or_measurement_approach":""}
Recruitment
- Planned Sample Size
- 322
- Recruitment Window Months
- 101
- Consent Approach
- Informed consent required; inability to provide informed consent is listed as an exclusion. A subject information and informed consent form document (SELDDEC Consent) is listed in the trial documents.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 322
Ireland
- Earliest CTIS Part Ii Submission Date
- 19-01-2025
- Latest Decision Or Authorization Date
- 07-05-2025
- Processing Time Days
- 108
- Number Of Sites
- 1
- Number Of Participants
- 322
Sites
- Site Name
- University Hospital Limerick
- Department Name
- General and Colorectal Surgery
- Principal Investigator Name
- Colin Peirce
- Principal Investigator Email
- colinpeirce@rcsi.ie
- Contact Person Name
- Colin Peirce
- Contact Person Email
- colinpeirce@rcsi.ie
- Number Of Participants
- 322
Sponsor
Primary sponsor
- Full Name
- University Hospital Limerick
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Ireland
Investigational products
- Investigational Product Name
- Erythromycin Tablets BP 250mg
- Active Substance
- ERYTHROMYCIN
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Marketing authorisation PL 40147/0036
- Maximum Dose
- 1 g
- Investigational Product Name
- Neomycin 500mg Tablets
- Active Substance
- NEOMYCIN SULPHATE PH. EUR.
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Marketing authorisation PL 20072/0223
- Maximum Dose
- 1 g
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia
- LENACAPAVIR, ISLATRAVIR for HIV-1 infection
- piperacillin sodium, tazobactam sodium for Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae severe infection